Brief: Nkgen Biotech’S Snk01 Nk Cell Therapy Cleared To Start Phase 2 Clinical Trial In Alzheimer’S Disease
20/05/2024 14:29
May 20 (Reuters) - Nkgen Biotech Inc NKGN.O :
* NKGEN BIOTECH’S SNK01 NK CELL THERAPY CLEARED TO START
PHASE 2
CLINICAL TRIAL IN ALZHEIMER’S DISEASE
* NKGEN BIOTECH INC: ADVANCES SNK01 INTO PHASE 2 IN MODERATE
ALZHEIMER'S DISEASE; FIRST PATIENT ENROLLED IN PHASE 2 EXPECTED
IN Q2 2024
Source text for Eikon: ID:nGNX8jZZR7
Further company coverage: NKGN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nkgen Biotech
See all newsBrief: Nkgen Biotech Expands Clinical Trial Site Network For Alzheimer’S Disease Program Across US
Brief: NKgen Biotech And Hekabio Enter Into Strategic Partnership
Brief: Nkgen Biotech Announces International And U.S. Expansion Of Phase 1/2A Troculeucel Alzheimer’S Trial
Brief: Nkgen Biotech Announces Administration Of First Dose Of Troculeucel To Stroke Patient Under FDA-Cleared Compassionate Use Program
Brief: NKGen Biotech Announces Administration Of First Dose Of Troculeucel To Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program